Teprotumumab therapy shows sustained proptosis improvement in clinical thyroid eye disease

Teprotumumab therapy has shown significant effectiveness in reducing proptosis in patients with clinical thyroid eye disease (TED), with nearly 90% of patients experiencing initial improvement after treatment, according to a study. However, the study also found that about two-thirds of patients experienced regression, typically within the first year after treatment,...